-
Ocumension Therapeutics’ OT-101-S Myopia Treatment Accepted for CDE Review
•
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced that the Center for Drug Evaluation (CDE) has accepted the Phase III clinical filing for its in-house developed OT-101-S, a treatment aimed at delaying or arresting child myopia. This development marks a significant step forward in the advancement of this novel…
-
Beijing Intellectual Property Court Upholds Validity of Novartis’ Entresto Patent
•
The Beijing Intellectual Property Court (BIPC) has issued a judgment that reaffirms the validity and enforceability of a core patent for Swiss pharmaceutical giant Novartis’s (NYSE: NVS) hypertension therapy, Entresto (sacubitril, valsartan), based on modified claims. The patent in question, No. ZL200680001733.0, titled “drug combination product of angiotensin II receptor…
-
Johnson & Johnson Reports 7.5% YOY Sales Growth in Q2 2023, Driven by Pharma and Devices
•
Johnson & Johnson (J&J; NYSE: JNJ) has published its financial results for the second quarter of 2023, reporting robust sales growth of 7.5% year-on-year (YOY) in constant currency terms, reaching USD 25.5 billion. The performance was driven by all business segments, with the pharmaceutical unit Janssen expanding by 3.8% YOY…
-
Sartorius Expands Global Footprint with New Cell Culture Facility in Puerto Rico
•
Germany-based laboratory services firm Sartorius has expanded its operations with the opening of a new cell culture facility in Puerto Rico, following an investment of USD 33 million. The 2,000 square meter site is designed to manufacture culture media used in the production of protein-based drugs, catering specifically to the…
-
Sandoz Plans USD 90 Million Biosimilar Development Center in Slovenia by 2026
•
The Sandoz unit of Switzerland-based Novartis (NYSE: NVS) has announced plans to construct a biosimilar development center in Slovenia by 2026, with an investment of approximately USD 90 million. This new project complements an existing generics plant and a planned biologic drugs factory in the country, valued at over USD…
-
Johnson & Johnson Files Lawsuit Against US Government’s Drug Pricing Negotiation Authority
•
United States-based Johnson & Johnson (J&J, NYSE: JNJ) has filed a lawsuit this week, challenging the US government’s authority to negotiate the price of selected drugs for the 2026 period onwards through the elderly health insurance program, Medicare. The company argues that such a project would damage innovation and potentially…
-
GSK Partners with LimmaTech for Further Development of Quadrivalent Shigellosis Vaccine
•
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has licensed its quadrivalent bioconjugate shigellosis vaccine candidate to Switzerland’s LimmaTech Biologics for further development and commercialization. This strategic move builds upon GSK’s acquisition of LimmaTech’s predecessor company, GlycoVaxyn, in 2015, which included the vaccine in its portfolio. Phase I/II Development and Multivalent…
-
Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip
•
US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second quarter of 2023, reporting strong revenue and profit growth that exceeded analysts’ consensus. Despite a significant drop in sales of COVID-19 diagnostics from USD 2.3 billion a year ago to just USD 263 million in…
